Teleflex ’ s NeoTract wins Japanese approval for UroLift BPH treatment system
Teleflex (NYSE:TFX) subsidiary NeoTract said today it won Shonin approval from Japan’s Ministry of Health, Labor and Welfare for its Urolift system intended for treating benign prostatic hyperplasia. The UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Pleasanton, Calif.-based company said. NeoTract said that it estimates there are approximately 2.3 million men age 50 and older in Japan who have been diagnosed with BPH. The company said that now that it has rec...
Source: Mass Device - November 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Featured Regulatory/Compliance Urology NeoTract Source Type: news

The Japanese rush can be used to prevent and treat the enlargement of the prostate
(Natural News) Talk about medicinal plants, and the first thing that people imagine is a shrub in the middle of nowhere. However, a study in BMC Complementary and Alternative Medicine found that the Japanese rush, a common plant seen in gardens around the world, could be used to treat benign prostatic hyperplasia (BPH), a noncancerous enlargement of... (Source: NaturalNews.com)
Source: NaturalNews.com - November 5, 2018 Category: Consumer Health News Source Type: news

Expect Boston Scientific to Keep Rounding Out Its Portfolio with M & amp;A
 Boston Scientific has been on quite the shopping spree in 2018. The Marlborough, MA-based company has announced eight acquisitions since the beginning of the year, plus a hefty investment in Millipede, which is likely to lead to an acquisition within the next year or so. Naturally, the company's aggressive M&A strategy has attracted attention from industry analysts who are eager to see if this spree will continue in 2019. During the company's third-quarter earnings call on Thursday, CFO Daniel Brennan said Boston Scientific still has a "tremendous amount" of financial flexibility. Loo...
Source: MDDI - October 25, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Teleflex ’ s NeuroTract touts UK Urolift decision
Teleflex (NYSE:TFX) subsidiary NeoTract said today that the UK Government selected the UroLift system, intended to treat patients with benign prostatic hyperplasia, as one of seven Accelerated Access Collaborative “Rapid Uptake Products.” The Wayne, Penn.-based company said that the system will now receive support from the Accelerated Access Collaborative which will increase its use by the UK’s NHS. The decision to include the device in the list follows its placement last year by NHS England as a recipient of the Innovation and Technology Tariff, which also helped support uptake of the trea...
Source: Mass Device - October 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Teleflex Source Type: news

Steam treatment for BPH: Mayo Clinic Radio Health Minute
It's a common problem for older men?? benign prostatic hyperplasia, or BPH. "BPH is a fancy way of saying the prostate is getting larger, and we don't want it to," says Dr. Toby Kohler, a Mayo Clinic urologist. In this Mayo Clinic Radio Health Minute, Dr. Kohler describes a new approach for treatment of BPH. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 17, 2018 Category: Databases & Libraries Source Type: news

Boston Scientific & #039;s Aggressive M & amp;A Strategy Continues with Augmenix Deal
Tuck-in acquisitions continue to play a key role in Boston Scientific's strategy this year, as evidenced by the company's latest deal, which also happens to be its largest so far in 2018.  The Marlborough, MA-based company has agreed to pay $500 million upfront and up to $100 million for sales-based milestones to acquire Augmenix. This private company is based in Bedford, MA and has developed a product called SpaceOAR, which intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy. Not only is Augmenix the eighth acquisition Boston Scientific has reported this yea...
Source: MDDI - September 7, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Boston Scientific puts up $600m for Augmenix
Boston Scientific (NYSE:BSX) said yesterday that it put $600 million on the table for Augmenix and its SpaceOar device. The deal for Bedford, Mass.-based Augmenix calls for $500 million in up-front cash and another $100 million pegged to sales-based milestones, Boston said. The SpaceOar hydrogel device, which won CE Mark approval in the European Union in 2010 and 510(k) clearance from the FDA in April 2015 , is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer. The product is delivered through a small needle as a liquid, which then solidifies into a so...
Source: Mass Device - September 7, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Augmenix Inc. Boston Scientific Source Type: news

Surgery-First Strategy Cost-Effective in Benign Prostatic Hyperplasia Surgery-First Strategy Cost-Effective in Benign Prostatic Hyperplasia
Using surgery as an initial treatment for moderate-to-severe benign prostatic hyperplasia (BPH) is more economically attractive than upfront pharmacotherapy followed by surgery for those who fail, researchers from Canada report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Study examines relationship between social disparities and benign prostatic hyperplasia
(Wiley) In an Andrologia study of 100,000 men in Korea, social disparities -- such as low education level and low household income, current or previous use of medical aid health insurance, blue-collar employment or unemployment, divorce, and low social capital of communities -- were all linked with a higher prevalence of benign prostatic hyperplasia (BPH), a condition that is characterized by an enlarged prostate due to aging, lower urinary tract blockage, and other factors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 22, 2018 Category: International Medicine & Public Health Source Type: news

Aquablation May Improve Symptoms in Men With Large Prostates Aquablation May Improve Symptoms in Men With Large Prostates
Aquablation, which uses robotically guided waterjets to remove excess prostate tissue, appears to improve lower-urinary-tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) and large prostate glands, researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 14, 2018 Category: Surgery Tags: Urology News Source Type: news

OmniGuide to buy German urological laser-maker
OmniGuide (Cambridge, Mass.) plans to acquire Lisa Laser Products, a surgical laser company based in Katlenburg-Lindau, Germany. Terms were not disclosed. Lisa Laser’s product portfolio consists of laser hardware units, laser fibers, endoscopes and other accessories for laser-assisted surgery. The company has been developing surgical laser technologies consisting of both thulium and holmium lasers for the treatment of benign prostatic hyperplasia, since 1989. More than half of men in the United States will develop the condition by age 60, and 30 million already have it, according to the American Urological ...
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Urology lisalaser OmniGuide Source Type: news

Medical News Today: What are the treatment options for BPH?
Benign prostatic hyperplasia, or BPH, is the medical term for an enlarged prostate. BPH can cause difficulties with urination. Treatment options for BPH include watchful waiting, medication, minimally invasive procedures, and surgery. Lifestyle changes can also help improve a person ’s symptoms. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

New treatment option available for men suffering from benign prostatic hyperplasia
(University of California - San Diego) Physicians at UC San Diego Health are now offering prostate artery embolization as a new treatment option for men with benign prostatic hyperplasia, or an enlarged prostate. The minimally invasive procedure is an alternative to surgery, with no hospital stay, little operative pain and lower cost. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Zydus Cadila gets USFDA nod for prostate condition treatment drug
The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) -- also called prostate gland enlargement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 25, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Can saw palmetto reduce enlarged prostate?
Saw palmetto is an herbal remedy with many potential uses in healthcare. One such use is the treatment of benign prostate hyperplasia (BPH). Although a popular remedy, research into the herb ’s efficacy is still ongoing and the results to date are inconclusive. Here, we look at the other treatments also available. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 24, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Medical News Today: Can BPH cause kidney failure?
Benign prostatic hyperplasia (BPH) refers to enlargement of the prostate that is unrelated to cancer. Because of the positions of the prostate and kidneys, an enlarged prostate can cause kidney, or renal, failure. Knowing the symptoms can ensure quick treatment. Learn about the links between renal failure and BPH here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Medical News Today: Is green tea good for BPH?
There are many potential treatments for an enlarged prostate or benign prostatic hyperplasia (BPH). Many people look to green tea to manage their BPH, and the science suggests that it may offer relief for some symptoms, and provide other health benefits. Learn more about green tea for BPH, and whether it works, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Procept BioRobotics touts early results from AquaBeam BPH waterjet ablation trial
Procept BioRobotics today released early results from a study of its AquaBeam waterjet ablation therapy system designed for the endoscopic resection of prostate tissue exploring its use in treating benign prostatic hyperplasia, touting that it already met its primary safety and efficacy endpoints. Results were presented at the American Urological Association’s annual meeting in San Francisco by study co-principal investigator Dr. Mihir Desai of the Keck School of Medicine of USC, the Redwood Shores, Calif.-based company said. The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue wi...
Source: Mass Device - May 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Robotics Urology Procept BioRobotics Source Type: news

Teleflex ’ s NeoTract wins AUA support for UroLift system as standard-of-care
Teleflex (NYSE:TFX) subsidiary NeoTract said today that the American Urological Association now recommends the use of NeoTract’s UroLift system as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. The company’s UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Pleasanton, Calif.-based company said. In a set of newly released clinical guidelines, the AUA recommends that the UroLift prostatic urethral lift pro...
Source: Mass Device - May 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Teleflex Source Type: news

Mayo Clinic Q and A: New steam treatment for benign prostatic hyperplasia
DEAR MAYO CLINIC: I was diagnosed with benign prostatic hyperplasia four years ago. It didn?t bother me at first, so my health care provider recommended watchful waiting. But now it?s causing quite a few problems, and we?re talking about surgery. I heard there?s a new treatment for benign prostatic hyperplasia that involves steam. Does it [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 8, 2018 Category: Databases & Libraries Source Type: news

Boston Scientific Closes NxThera Acquisition
MARLBOROUGH, Mass., April 30, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive thera... Devices, Urology, Mergers & Acquisitions Boston Scientific, NxThera, Rezum system, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

Boston Scientific closes $400m NxThera buy
Boston Scientific (NYSE:BSX) said today that closed the $406 million acquisition of NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal called for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $85 million on the table in milestones. NxThera is based in ...
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Boston Scientific NxThera Inc. Source Type: news

New prostate therapy recommended on NHS
It's non-surgical and can treat an enlarged, non-cancerous condition called benign prostatic hyperplasia. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 24, 2018 Category: Consumer Health News Source Type: news

Embolx wins $2m NIH grant for pressure-directed embolization therapy
Embolx said today that it landed a $2 million grant from the National Cancer Institute to fund development of its next-generation Sniper balloon occlusion microcatheter. The Sunnyvale, Calif.-based medical device company has developed a drug-delivery system that administers therapies into targeted areas of the body by controlling pressure. Embolx’s Sniper balloon is designed to treat cancerous tumors, benign prostatic hyperplasia and uterine fibroids, according to the company. Get the full story at our sister site, Drug Delivery Business News. The post Embolx wins $2m NIH grant for pressure-directed emboliz...
Source: Mass Device - April 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Research & Development embolx National Institutes of Health (NIH) Source Type: news

Boston Scientific, Mayo Clinic back new Minneapolis medtech incubator
Boston Scientific (NYSE:BSX) is joining the Mayo Clinic and the University of Minnesota in backing startup accelerator Gener8tor as it launches a medtech focused incubator in Minneapolis, according to a new report from the Minneapolis Star Tribune. The newly launched accelerator will operate under a seven-week program that will support six new startups with a focus on medical technology, requiring no fees or equity and offered three times a year, according to the report. Initial entrants into the incubator include wearable-focused medical tape maker ExpressionMed, cardiac rhythm and neuromod dev Kobara Medical, interv...
Source: Mass Device - March 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Boston Scientific Mayo Clinic Source Type: news

UPDATE: Boston Scientific lays out $406m for NxThera which plans spin-out of cancer treatment tech
Updated to include commentary from NxThera prez & CEO Bob Paulson. Boston Scientific (NYSE:BSX) said today that it laid out a $406 million deal for NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal calls for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $8...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Boston Scientific NxThera Inc. Source Type: news

March Madness: Boston Scientific Continues Buying Spree
Boston Scientific is set to acquire NxThera, a urology specialist, for about $406 million. The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. The deal is set to close in the second quarter of 2018. Maple Grove, MN-based NxThera has developed and commercialized the Rezūm system, which is a minimally invasive therapy for the treatment of symptoms arising from benign prostatic hyperplasia (BPH). The system was cleared by FDA in 2015 and has CE mark. Treatment with the Rezūm system is typicall...
Source: MDDI - March 21, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Boston Scientific Announces Agreement To Acquire NxThera
Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia MARLBOROUGH, Mass., March 21, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (NYSE: BSX) today announced that it ... Devices, Urology, Mergers & Acquisitions Boston Scientific, NxThera, Rezūm, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2018 Category: Pharmaceuticals Source Type: news

Benign prostatic hyperplasia —gaining insight and potential new treatment identified in mice
New information on the potential role of fibrosis in benign prostatic hyperplasia (BPH) could offer insights into how fibrosis occurs in other tissues. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Teleflex ’ s NeoTract wins expanded FDA indication for UroLift prostate device
Teleflex (NYSE:TFX) subsidiary NeoTract said yesterday that it won expanded indications from the FDA for its UroLift prostate treatment. Previously approved for treating benign prostate hyperplasia in men 50 and over without an obstructive median lobe, the new indications open the treatment to patients 45 or older with an obstructive median lobe. UroLift uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. “We are excited that more men with enlarged prostate are now eligibl...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Regulatory/Compliance Urology Wall Street Beat NeoTract Teleflex Source Type: news

Procept BioRobotics raises $118m for Aquablation prostate treatment
Procept BioRobotics said today that it raised $118 million in an equity round it plans to use on the commercialization of its Aquablation treatment for benign prostate hyperplasia. Redwood Shores, Calif.-based Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG. The Aquablation treatment combines Procept’s Aquabeam – a high-pressure water jet used to remove prostate tissue without heating it – with imaging and surgical robotics technology. It won de novo clearance from the FDA last December; at the time...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Robotics Urology Wall Street Beat Procept BioRobotics Source Type: news

Medical News Today: What are the effects of an enlarged prostate on sex?
Learn about how benign prostatic hyperplasia can affect sexual function. We look at the effects and treatment options, including surgery, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 19, 2018 Category: Consumer Health News Tags: Sexual Health / STDs Source Type: news

Zenflow raises $31m in Series A
Urology medical device maker Zenflow said today it closed a $31.4 million Series A round of financing to support the development of minimally invasive devices designed to treat obstructive urinary symptoms related to benign prostatic hyperplasia. The round was led by Invus Opportunities, F-Prime Capital Partners and Medical Technology Venture Partners and was joined by other new and existing investors, the San Francisco-based company said. Zenflow said it has also received grant funding from the National Institutes of Health and the National Science Foundation. The company’s first product is the Spring System device,...
Source: Mass Device - February 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology zenflow Source Type: news

NxThera touts 3-year Rez ūm trial results
NxThera today released three-year results from a trial of its Rezūm convective water vapor wave energy system, touting effective and durable relief from lower urinary tract symptoms for patients with benign prostatic hyperplasia. The trial was co-authored by co-principal investigators Dr. Kevin McVary of Southern Illinois University School of Medicine and Dr. Claus Roehrborn of the University of Texas Southwestern Medical Center, and results were published in the January 2018 issue of the journal Urology. “Rezūm warrants consideration as a first-line treatment for BPH due to the durability of LUTS relief out t...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Urology NxThera Inc. Source Type: news

Butterfly Medical wins CE Mark for in-office benign prostate hyperplasia device
Medical device developer Butterfly Medical said today it won CE Mark approval in the European Union for its device designed for the in-office treatment of benign prostate hyperplasia. The Israel-based company’s device is designed to dilate the prostatic urethra without any surgical incisions or prostate tissue removal. The device then secures tightly to the prostate tissue to prevent migration to move the lobes of the prostate out of the way and improve urine flow. “We are proud to bring a simple, non-surgical treatment option to the millions of men worldwide afflicted by BPH. With our Butterfly Medic...
Source: Mass Device - November 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Urology butterflymedical Source Type: news

Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Teleflex closes $1B NeoTract buy
Teleflex (NYSE:TFX) said today that it closed its $1.1 billion acquisition of NeoTract and its UroLift prostate treatment. The deal called for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last year, up 178% over 2015, and...
Source: Mass Device - October 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat NeoTract Teleflex Source Type: news

Procept BioRobotics treats first patients in Water II test of surgical robot
Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients at up to 20 sites in the U.S. and Canada. Read the full story on our sister site, The Robot Report. The post Procept BioRobotics treats first patients in Water II test of surgical robot appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 27, 2017 Category: Medical Devices Authors: Alex Beall Tags: Biotech Research & Development Robotics Surgical Urology Procept BioRobotics Source Type: news

Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) QuizCategory: MedicineNet QuizCreated: 2/7/2012 3:29:00 PMLast Editorial Review: 9/20/2017 12:17:12 PM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - September 20, 2017 Category: Primary Care Source Type: news

Medical News Today: Six yoga poses for prostate enlargement
Yoga has many benefits, In this article, learn about six yoga poses that can help ease and manage the symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Men's Health Source Type: news

Merit Medical licenses KatGuide pleural drain tech from Pleuratech
Merit Medical (NSDQ:MMSI) has licensed a novel surgical device designed to ensure drain placement in the pleural cavity from Pleuratech, according to a Young America Capital press release posted this week. The device is Denmark-based Pleuratech’s flagship product, the KatGuide, and is designed to guide chest tubes to the part of the pleural cavity which needs draining to reduce misplaced drains and increase surgical success rates. The companies did not release the exact terms of the deal, but said that it was a multimillion dollar license agreement, according to a press release. “As a leading manufacturer ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Surgical Merit Medical Systems Inc. pleuratech Source Type: news

Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH
Photoselective vaporization of the prostate (PVP) offers similar efficacy with better quality of life, compared with transurethral resection of the prostate (TURP), in men with benign prostatic hyperplasia (BPH), researchers from Italy report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

How Teleflex Bagged a $1.1 Billion Hidden Treasure
Teleflex CEO Benson Smith expected some investors to be surprised by yet another billion-dollar acquisition, but sometimes businesses simply must strike while the iron is hot. The Wayne, PA-based company said it will buy NeoTract for up to $1.1 billion. The deal comes just seven months after Teleflex completed its $1 billion acquisition of Vascular Solutions. "I'm sure that at least some of you may be a bit surprised that Teleflex is once again active in M&A so quickly after announcing the acquisition of Vascular Solutions. Well, we are not," Smith said Tuesday during a conference call. Smith said Teleflex ha...
Source: MDDI - September 5, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Teleflex to pay $1.1B for NeoTract
Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment. The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughl...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat NeoTract Teleflex Source Type: news

NxThera adds $6m for Rez ūm prostate device
NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise an additional $5.8 million in the round, taking the total hoped-for raise from $15 million to $26.4 million. In Dec. 2015, Boston Scientific (NYSE:BSX) led a $40 million funding round for NxThera and its Rezūm device, saying it plans to boost its sales footprint in the U.S. an...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat NxThera Inc. Source Type: news

7 medtech stories we missed this week: July 7, 2017
[Image from unsplash.com]From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EnvisionTEC wins FDA nod for 3D printing E-Denture material EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital den...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Dental Food & Drug Administration (FDA) Imaging Implants Research & Development Adin Dental Implant Systems EnvisionTEC InVivo Therapeutics Life Spine Inc. MedTech NeoTract SpineGuard SpineWave Telerad Tech Ze Source Type: news

Tamsulosin and Naftopidil Offer Similar Benefits in BPH Tamsulosin and Naftopidil Offer Similar Benefits in BPH
Bladder storage symptoms associated with benign prostatic hyperplasia (BPH) improve to a similar extent with tamsulosin and naftopidil treatment, researchers from South Korea report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants de novo clearance for Merit Medical ’ s Embosphere
Merit Medical (NSDQ:MMSI) said yesterday that its Embosphere device won expanded de novo clearance from the  to treat benign prostatic hyperplasia. The federal safety watchdog’s clearance means Embosphere can be used in prostatic artery embolization  procedures to treat BPH. “Merit’s Embosphere is the first embolic agent to receive FDA 513(f)(2) classification for prostatic artery embolization, providing a non-surgical treatment option for millions of men who suffer from BPH,” chairman & CEO Fred Lampropoulos said in prepared remarks. The device is designed to occlude th...
Source: Mass Device - June 23, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Urology Merit Medical Systems Inc. Source Type: news

Popular prostate drug linked to serious side effects
(Boston University Medical Center) Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2017 Category: International Medicine & Public Health Source Type: news

2017 Eureka! Innovation award winner: NxThera Inc.
Industry category: Health Care Technology Organization size: Small — revenue less than $50 million Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible." Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2017 Category: Biotechnology Source Type: news